(MENAFN- GlobeNewsWire – Nasdaq) Coloplast, a leading intimate health care company, will invest approximately €100 million in a new production site in Portugal to further grow.
The new production facility will produce Coloplast’s intermittent catheters used by others with urinary retention, such as others with spinal cord injury or spina bifida, who are unable to empty their bladder. With this new location, Coloplast aims to meet developing global needs. demand for intermittent catheters, with demand in Europe, which is the company’s largest market, accounting for approximately 60% of its total sales. Although Europe is a more mature market, Coloplast continues to see strong demand for its intermittent catheters, with continued expansion demand outpacing the market.
“We chose Portugal as a destination for our next production site for several reasons. Most importantly, Portugal has a professional and highly professional workforce with an excellent salary level. It is also vital that Portugal is in Europe, where we serve the maximum of our current users and where more and more people will want our products in the coming years. This destination allows us to diversify our commercial footprint in Europe, which lately is concentrated in Hungary. Finally, the country has an important source of renewable electrical energy and has the ambition to be carbon neutral until 2050, supporting our sustainability ambition,” says Allan Rasmussen, Executive Vice President of Global Operations.
Coloplast’s long-term bio-based expansion ambition of 8-10% annually requires the company to identify a new production site within one to two to three years to meet developing demand. Coloplast has a global production network with high-volume production facilities in Hungary. , China and Costa Rica, specialized production in the United States, France, Germany, Sweden and Iceland, as well as a pilot and innovation plant in Denmark. The new headquarters in Portugal will have an area of 30,000 m2, Coloplast’s largest to date, and is expected to be operational from 2026.
Global Operations Plan 6 The new site in Portugal is a component of Coloblast’s Global Operations Plan 6 (GOP6) “Ready for the Future”. Like previous Global Operations Plans, GOP6 continues to focus on effective operations in several other avenues and initiatives. The aim is the long-term expansion and progression of the company’s profitability and allows Coloplast to generate a long-term EBIT margin of more than 30%.
Contacts
Peter MonsterMr. Media Relations Manager, Corporate Communications forty-five 4911 2623
Aleksandra DimovskaMr. Director of Investor Relations forty-five 4911 2forty-five8
Attached
MENAFN09112023004107003653ID1107398141
Keywords
comment
Category
Date